S. Goodstal

发表

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Xiaohong Liu, S. Château-Joubert, I. Bièche, 2012, Molecular Cancer Therapeutics.

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells

R. Engh, C. Peschel, J. Duyster, 2014, PloS one.

Preclinical Development Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Xiaohong Liu, S. Château-Joubert, M. Poupon, 2012 .

Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer

Arvind Rao, Geoffrey Bartholomeusz, Justin Jacob, 2015, Journal of Cancer.

SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors.

Xuliang Jiang, B. Huck, H. Tian, 2013, Bioorganic & medicinal chemistry letters.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

T. Hagemann, D. Hochhauser, J. Hartley, 2015, Clinical Cancer Research.

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.

L. Cascione, A. Stathis, E. Gaudio, 2016, Annals of Oncology.

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models

B. Elenbaas, D. Hochhauser, J. Hartley, 2018, Oncotarget.

Abstract LB-456: Evaluation of brain pharmacokinetics as a potential differentiation factor for the MEK inhibitors, MSC2015103 and pimasertib

Hong Zhang, H. Tian, A. Clark, 2012 .

THE MEK1/2 INHIBITOR PIMASERTIB ENHANCES GEMCITABINE EFFICACY IN PANCREATIC CANCER MODELS BY ALTERING PROTEIN LEVELS OF RIBONUCLEOTIDE REDUCTASE SUBUNIT-1 (RRM1)

T. Hagemann, D. Hochhauser, J. Hartley, 2015 .

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.